Management of Candida infections in the adult intensive care unit

Bibliography

• Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996;9(4):499-511
   PubMed Web of Science ®Google Scholar
• Henderson VJ, Hirvela ER. Emerging and reemerging microbial threats. Nosocomial fungal infections. Arch Surg 1996;131(3):330-7
   PubMedGoogle Scholar
• Beck-Sague CM, Jarvis WR. National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980 – 1990. J Infect Dis 1993;167(5):1247-51
   Google Scholar
• Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European prevalence of infection in intensive care (EPIC) study. JAMA 1995;274(8):639-44
   PubMed Web of Science ®Google Scholar
• Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29(2):239-44
   PubMed Web of Science ®Google Scholar
• Pittet D, Wenzel RP. Nosocomial bloodstream infections. Secular trends in rates, mortality and contribution to total hospital deaths. Arch Intern Med 1995;155(11):1177-84
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Jones RN, et al.; SENTRY Participant Group. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001;39(9):3254-9
   PubMed Web of Science ®Google Scholar
• Marchetti O, Bille J, Fluckiger U, et al. Fungal Infection Network of Switzerland. Epidemiology of candidaemia in Swiss tertiary care hospitals: secular trends 1991 – 2000. Clin Infect Dis 2004;38(3):311-20
   PubMed Web of Science ®Google Scholar
• Voss A, Noble JL, Verduyn-Lunel FM, et al. Candidemia in ICU patients: risk factors for mortality. Infection 1997;25(1):10-3
   Google Scholar
• Vincent JL, Anaissie E, Bruining H, et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998;24(10):206-16
   PubMed Web of Science ®Google Scholar
• Blumberg HM, Jarvis WR, Soucie JM, et al. National Epidemiology of Mycoses Survey (NEMIS) Study Group. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001;33(2):177-86
   PubMed Web of Science ®Google Scholar
• Sobel JD, Rex JH. Invasive candidiasis: turning risk into a practical prevention policy? Clin Infect Dis 2001;33(2):187-90
   PubMedGoogle Scholar
• Tortorano AM, Peman J, Bernhardt H, et al. ECMM Working Group on Candidaemia: epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004;23(4):317-22
   PubMed Web of Science ®Google Scholar
• Petri MG, Konig J, Moecke HP, et al. Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive Care Med 1997;23(3):317-25
   PubMed Web of Science ®Google Scholar
• Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999;29(2):253-8
   PubMed Web of Science ®Google Scholar
• Barnes RA. Risk factors for Candida infection in the intensive care unit. European perspectives. In: Fungal Infections in the Intensive Care Unit. Series: Perspectives on Critical Care Infectious Diseases, Volume 6. Barnes RA, Warnock DW, editors. Springer Verlag; 2002. p. 45-54
   Google Scholar
• Nguyen MH, Peacock JE, Morns AJ, et al. The changing face of Candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996;100(6):617-23
   PubMed Web of Science ®Google Scholar
• Rocco TR, Reinert SE, Simms HH. Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg 2000;135(2):160-5
   PubMed Web of Science ®Google Scholar
• Berrouane YF, Herwaldt LA, Pfaller MA. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol 1999;37(3):531-7
   PubMed Web of Science ®Google Scholar
• Gleason TG, May AK, Caparelli D, Farr BM, Sawyer RG. Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units. Arch Surg 1997;132(11):1197-201
   PubMedGoogle Scholar
• Shelenz S, Gransden WR. Candidemia in a London teaching hospital: analysis of 128 cases over a 7 years period. Mycoses 2003;46(9-10):390-6
   PubMedGoogle Scholar
• Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002;50(1):56-65
   PubMed Web of Science ®Google Scholar
• McMullan R, McClurg R, Xu J, et al. Trends in the epidemiology of Candida bloodstream infections in Northern Ireland between January 1984 and December 2000. J Infect 2002;45(1):25-8
   PubMedGoogle Scholar
• Bassetti M, Righi E, Costa A, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006;6:21
   PubMed Web of Science ®Google Scholar
• Luzzati R, Allegranzi B, Antozzi L, et al. Secular trends in nosocomial candidaemia in non-neutropenic patients in an Italian tertiary hospital. Clin Microbiol Infect 2005;11(11):908-13
   PubMed Web of Science ®Google Scholar
• Tortorano AM, Caspani L, Rigoni AL, et al. Candidosis in the intensive care unit: a 20-year survey. J Hosp Infect 2004;57(1):8-13
   PubMedGoogle Scholar
• Almirante B, Rodriguez D, Park BJ, et al. Barcelona Candidemia Project Study Group. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005;43(4):1829-35
   PubMed Web of Science ®Google Scholar
• Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006;25(7):419-25
   PubMed Web of Science ®Google Scholar
• Colombo AL, Nucci M, Salomao R, et al. High rate of non-albicans candidemia in Brazilian tertiary care hospitals. Diagn Microbiol Infect Dis 1999;34(4):281-6
   PubMed Web of Science ®Google Scholar
• Nolla-Salas J, Sitges-Serra A, Leon-Gil C, et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997;23(1):23-30
   PubMed Web of Science ®Google Scholar
• Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989 – 1999. Clin Infect Dis 2002;35(5):627-30
   PubMed Web of Science ®Google Scholar
• Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003;3(12):772-85
   PubMed Web of Science ®Google Scholar
• Lipsett PA. Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: concepts and considerations. Clin Infect Dis 2004;39(Suppl 4):S193-9
   Google Scholar
• Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220(6):751-8
   PubMed Web of Science ®Google Scholar
• Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Hammond JM, Hendrix CW. The diagnostic value of fungal surveillance cultures in critically ill patients. Surg Infect 2000;1(4):273-81
   PubMedGoogle Scholar
• Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989;149(10):2349-53
   PubMed Web of Science ®Google Scholar
• Lipman J, Saadia R. Fungal infections in critically ill patients. BMJ 1997;315(3103):266-7
   PubMedGoogle Scholar
• Piarroux R, Grenouillet F, Balvay P, et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004;32(12):2443-9
   PubMed Web of Science ®Google Scholar
• Fleming RV, Walsh TJ. Risk factors for Candida infection in the intensive care unit. North Americas perspectives. In: Barnes RA, Warnock DW, editors. Fungal Infections in the Intensive Care Unit. Series: Perspectives on Critical Care Infectious Diseases, Volume 6. Springer Verlag; 2002. p. 23-44
   Google Scholar
• Fluckiger U, Marchetti O, Bille J, et al. Fungal Infection Network of Switzerland (FUNGINOS). Treatment options of invasive fungal infections in adults. Swiss Med Wkly 2006;136(29-30):447-63
   Google Scholar
• Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000;30(4):662-78
   PubMed Web of Science ®Google Scholar
• British Society for Antimicrobial Chemotherapy Working Party. Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med 1994;20(7):522-8
   PubMedGoogle Scholar
• Peleg AY, Woods ML. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother 2004;54(4):803-8
   PubMed Web of Science ®Google Scholar
• Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003;36(8):943-51
   PubMed Web of Science ®Google Scholar
• Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001;322(7286):579-82
   PubMed Web of Science ®Google Scholar
• Furrer K, Schaffner A, Vavricka SR, et al. Nephrotoxicity of cyclosporine A and amphotericin B-deoxycholate as continuous infusion in allogenic stem cell transplantation. Swiss Med Wkly 2002;132(23-24):316-20
   PubMed Web of Science ®Google Scholar
• Barrett JP, Vardulaki KA, Conlon C, et al. Amphotericin B Systematic Review Study Group. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003;25(5):1295-320
   PubMed Web of Science ®Google Scholar
• Linden PK. Amphotericin B lipid complex for the treatment of invasive fungal infections. Expert Opin Pharmacother 2003;4(11):2099-110
   PubMed Web of Science ®Google Scholar
• Patel R. Amphotericin B colloidal dispersion. Expert Opin Pharmacother 2000;1(3):475-88
   PubMedGoogle Scholar
• Cornely OA, Maertens J, Bresnik M, et al. AmBiLoad Trial Study Group: Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44(10):1289-97
   PubMed Web of Science ®Google Scholar
• Offner F, Krcmery V, Boogaerts M, et al. EORTC Invasive Fungal Infections Group. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Antimicrob Agents Chemother 2004;48(12):4808-12
   PubMed Web of Science ®Google Scholar
• Krupova Y, Mistrik M, Bojtarova E, et al. Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients. Support Care Cancer 2001;9(3):209-10
   PubMedGoogle Scholar
• Carrillo-Munoz AJ, Giusiano G, Ezkurra PA, Quindos G. Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter 2006;19(2):130-9
   PubMedGoogle Scholar
• Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000;46(2):171-9
   PubMed Web of Science ®Google Scholar
• Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000;30(4):710-8
   PubMed Web of Science ®Google Scholar
• Bodey GP. Azole antifungal agents. Clin Infect Dis 1992;14(Suppl 1):S161-9
   PubMed Web of Science ®Google Scholar
• Charlier C, Hart E, Lefort A. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006;57(3):384-410
   PubMed Web of Science ®Google Scholar
• Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39(1):1-8
   PubMed Web of Science ®Google Scholar
• Pierard GE, Arrese JE, Pierard-Franchimont C. Itraconazole. Expert Opin Pharmacother 2000;1(2):287-304
   PubMedGoogle Scholar
• Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006;42(2):244-51
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rex JH, Sobel JD, et al. Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38(2):161-89
   PubMed Web of Science ®Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003;36(5):630-7
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34(5):56371
   Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):40815
   Google Scholar
• Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366(9495):1435-42
   PubMed Web of Science ®Google Scholar
• Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004;39(5):743-6
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346(4):22534
   Google Scholar
• Jorgensen KJ, Gotzsche PC, Johansen HK. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2006;25(1):CD004707
   Google Scholar
• Kwon DS, Mylonakis E. Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother 2007;8(8):1167-78
   PubMed Web of Science ®Google Scholar
• Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007;44(4):607-14
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356(4):348-59
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356(4):335-47
   PubMed Web of Science ®Google Scholar
• Johnson MD, Perfect JR. Caspofungin: first approved agent in a new class of antifungals. Expert Opin Pharmacother 2003;4(5):807-23
   PubMed Web of Science ®Google Scholar
• Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003;36(11):1445-57
   PubMed Web of Science ®Google Scholar
• Zaas AK, Alexander BD. Echinocandins: role in antifungal therapy, 2005. Expert Opin Pharmacother 2005;6(10):1657-68
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, et al. Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347(25):2020-9
   PubMed Web of Science ®Google Scholar
• Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39(6):797-802
   PubMed Web of Science ®Google Scholar
• Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006;43(8):1060-8
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Lewis JS 2nd. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother 2007;8(8):1155-66
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006;42(8):1171-8
   PubMed Web of Science ®Google Scholar
• Kuse ER, Chetchotisakd P, Da Cunha CA, et al. Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a Phase III randomised double-blind trial. Lancet 2007;369(9572):1519-27
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45(7):883-93
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356(24):2472-82
   PubMed Web of Science ®Google Scholar
• Yeo SF, Wong B. Current status of nonculture methods for diagnosis of invasive fungal infections. Clin Microbiol Rev 2002;15(3):465-84
   PubMed Web of Science ®Google Scholar
• Stevens DA. Diagnosis of fungal infections: current status. J Antimicrob Chemother 2002;49(Suppl 1):11-9
   PubMedGoogle Scholar
• Mitsutake K, Miyazaki T, Tashiro T, et al. Endolase antigen, mannan antigen, Cand-Tec antigen, and β-D-glucan in patients with candidemia. J Clin Microbiol 1996;34(8):1918-21
   PubMed Web of Science ®Google Scholar
• Obayashi T, Yoshida M, Mori T, et al. Plasma (1-3) β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995;345(8941):17-20
   PubMed Web of Science ®Google Scholar
• Odabasi Z, Mattiuzzi G, Estey E, et al. β-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004;39(2):199-205
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005;41(5):654-9
   PubMed Web of Science ®Google Scholar
• Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001;32(8):1191-200
   PubMed Web of Science ®Google Scholar
• Bow EJ, Laverdiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002;94(12):3230-46
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34(6):730-51
   PubMed Web of Science ®Google Scholar
• Zuccotti G, Strasfeld L, Weinstock DM. New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients. Expert Opin Pharmacother 2005;6(10):1669-79
   PubMed Web of Science ®Google Scholar
• Tiffany KF, Smith PB, Benjamin DK Jr. Neonatal candidiasis: prophylaxis and treatment. Expert Opin Pharmacother 2005;6(10):1647-55
   PubMed Web of Science ®Google Scholar
• Manzoni P, Stolfi I, Pugni L, et al. Italian Task Force for the Study and Prevention of Neonatal Fungal Infections; Italian Society of Neonatology. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007;356(24):2483-95
   PubMed Web of Science ®Google Scholar
• Cruciani M, Mengoli C, Malena M, et al. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006;12(5):850-8
   PubMed Web of Science ®Google Scholar
• Playford EG, Webster AC, Sorrell TC, Craig JC. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 2006;25(9):549-61
   PubMedGoogle Scholar
• Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999;27(6):1066-72
   PubMed Web of Science ®Google Scholar
• Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001;233(4):542-8
   PubMed Web of Science ®Google Scholar
• Garbino J, Lew DP, Romand JA, et al. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002;28(12):1708-17
   PubMed Web of Science ®Google Scholar
• Calandra T, Marchetti O. Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin Infect Dis 2004;39(Suppl 4):S185-92
   Google Scholar
• Cruciani M, De Lalla F, Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 2005;31(11):1479-87
   PubMed Web of Science ®Google Scholar
• Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev 2006;(1):CD0049
   Google Scholar
• Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis. Crit Care Med 2005;33(9):1928-35
   PubMed Web of Science ®Google Scholar
• Kauffman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001;345(23):16606
   Google Scholar
• León C, Ruiz-Santana S, Saavedra P, et al. EPCAN Study Group. A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006;34(3):730-7
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34(6):1589-96
   PubMed Web of Science ®Google Scholar
• Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994;331(20):1325-30
   PubMed Web of Science ®Google Scholar
• Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997;16(5):337-45
   PubMed Web of Science ®Google Scholar
• Rex JH, Pappas PG, Karchmer AW, et al. National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36(10):1221-8
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis 2002;34(5):591-9
   PubMed Web of Science ®Google Scholar
• Wise GJ. Genitourinary fungal infections: a therapeutic conundrum. Expert Opin Pharmacother 2001;2(8):1211-26
   PubMedGoogle Scholar
• Sobel JD, Kauffman CA, McKinsey D, et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. Clin Infect Dis 2000;30(1):19-24
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. Clin Infect Dis 2000;30(1):148
   Google Scholar
• Drew RH, Arthur RR, Perfect JR. Is it time to abandon the use of amphotericin B bladder irrigation? Clin Infect Dis 2005;40(10):1465-70
   PubMedGoogle Scholar
• Edwards JE Jr, Foos RY, Montgomerie JZ, Guze LB. Ocular manifestations of Candida septicemia: review of seventy-six cases of hematogenous Candida endophthalmitis. Medicine 1974;53(1):47-75
   PubMed Web of Science ®Google Scholar
• Sallam A, Lynn W, McCluskey P, Lightman S. Endogenous Candida endophthalmitis. Expert Rev Antiinfect Ther 2006;4(4):675-85
   PubMedGoogle Scholar
• Solomkin JS, Flohr AB, Quie PG, Simmons RL. The role of Candida in intraperitoneal infections. Surgery 1980;88(4):524-30
   PubMed Web of Science ®Google Scholar
• Calandra T, Bille J, Schneider R, et al. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989;2(8677):1437-40
   PubMed Web of Science ®Google Scholar
• El-Ebiary M, Torres A, Fabregas N, et al. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients: an immediate postmortem histologic study. Am J Respir Crit Care Med 1997;156(2 Pt 1):583-90
   PubMed Web of Science ®Google Scholar
• Rello J, Esandi ME, Diaz E, et al. The role of Candida sp isolated from bronchoscopic samples in nonneutropenic patients. Chest 1998;114(1):146-9
   PubMedGoogle Scholar
• Ascioglu S, Rex JH, De Pauw B, et al. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34(1):7-14
   PubMed Web of Science ®Google Scholar
• Lewis RE. Pharmacotherapy of Candida bloodstream infections: new treatment options, new era. Expert Opin Pharmacother 2002;3(8):1039-57
   PubMedGoogle Scholar
• Kim R, Khachikian D, Reboli AC. A comparative evaluation of properties and clinical efficacy of the echinocandins. Expert Opin Pharmacother 2007;8(10):1479-92
   PubMed Web of Science ®Google Scholar
• Johnson MD, Kleinberg M, Danziger L, Ostrosky-Zeichner L. Pharmacoeconomics of antifungal pharmacotherapy–challenges and future directions. Expert Opin Pharmacother 2005;6(15):2617-32
   PubMed Web of Science ®Google Scholar
• Dixon S, McKeen E, Tabberer M, Paisley S. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature. Pharmacoeconomics 2004;22(7):421-33
   PubMed Web of Science ®Google Scholar